Trial Profile
Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in non-depressed out-patients with severe Generalized Anxiety Disorder. A 12-week randomised, double-blind, versus escitalopram, 2-arm parallel groups, international multicenter study with a 9-month extension period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary) ; Escitalopram
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- Sponsors IRIS
- 27 Nov 2017 Status changed to completed.
- 02 Apr 2013 New trial record